AxoGen, Inc.
Health
Performance
5.9
Risk
Sell
Buy
Curious about the Scores? Learn more.

AxoGen, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

17.07.2026
Signs of control returning. Still shaky, but not chaos.
16.07.2026
Pulse detected. Still fragile, but stabilizing.
14.07.2026
Fragile setup. Still failing to meet the key marks today.
13.04.2026
Outperforming hard. Momentum locked in.
AXGN
AxoGen, Inc.
40.26
+1.98%
5.9
Sell
Buy
AxoGen, Inc.

AxoGen, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does AxoGen, Inc. do? Business model and key facts

Get the full picture of AxoGen, Inc.: what it builds, where it operates, and how it makes money.

AxoGen, Inc. Profile

Sector: Healthcare

Industry: Medical - Devices

Employees (FY): 622

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

shop
Company facts
Michael D. Dale
CEO
622
Employees worldwide
shop
Performance
240.05%
Last 12 months
97.89%
Last 5 years
shop
Growth
$225.21M
Revenue year
$-15,703,000
Net income
shop
Valuation
$2.12B
Market Cap
-96.26
Price/Earnings Ratio

Stocks related to AxoGen, Inc.

Selected based on industry alignment and relative market positioning.

TMDX
TransMedics Group, Inc.
74.29
+1.12%
8.8
Sell
Buy
TransMedics Group, Inc.
ESTA
Establishment Labs Holdings Inc.
95.65
+2.39%
6.1
Sell
Buy
Establishment Labs Holdings Inc.
ITGR
Integer Holdings Corporation
96.37
+0.29%
5.3
Sell
Buy
Integer Holdings Corporation
UFPT
UFP Technologies, Inc.
243.94
-0.68%
5.7
Sell
Buy
UFP Technologies, Inc.
NVCR
Novocure Ltd
15.99
+0.31%
7.9
Sell
Buy
Novocure Ltd

Events and news impacting AxoGen, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

AxoGen, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.